TY - JOUR
T1 - Visual Evoked Potential Abnormalities in Phelan-McDermid Syndrome
AU - Siper, Paige M.
AU - Rowe, Mikaela A.
AU - Guillory, Sylvia B.
AU - Rouhandeh, Audrey A.
AU - George-Jones, Julia L.
AU - Tavassoli, Teresa
AU - Lurie, Stacey
AU - Zweifach, Jessica
AU - Weissman, Jordana
AU - Foss-Feig, Jennifer
AU - Halpern, Danielle
AU - Trelles, M. Pilar
AU - Mulhern, Maureen S.
AU - Brittenham, Chloe
AU - Gordon, James
AU - Zemon, Vance
AU - Buxbaum, Joseph D.
AU - Kolevzon, Alexander
N1 - Funding Information:
This study was funded by the National Institute of Neurological Disorders and Stroke ( R01NS105845 and 1 U54 NS092090 to A.K.), the National Institute of Mental Health ( R34 MH100276 to A.K. and R21MH107839 to J.D.B.), the Phelan-McDermid Syndrome Foundation, and the Beatrice & Samuel A. Seaver Foundation.
Funding Information:
This study was funded by the National Institute of Neurological Disorders and Stroke (R01NS105845 and 1 U54 NS092090 to A.K.), the National Institute of Mental Health (R34 MH100276 to A.K. and R21MH107839 to J.D.B.), the Phelan-McDermid Syndrome Foundation, and the Beatrice & Samuel A. Seaver Foundation.Disclosure: Dr. Gordon has reported serving as a consultant for VeriSci Corp., a company that manufactured the Neucodia system. Dr. Zemon has reported serving as a principal in VeriSci Corp., a company that manufactured the Neucodia system. Drs. Gordon and Zemon have reported being shareholders in VeriSci Corp., which has a licensing agreement with Konan Medical USA. Dr. Buxbaum and Mount Sinai have reported holding a patent for the use of Insulin-Like Growth Factor-1 in the treatment of Phelan-McDermid syndrome. Dr. Kolevzon has received research support from AMO Pharma and has served as a consultant to Ovid, Alkermes, Ritrova, Acadia, and Jaguar Therapeutics. Drs. Siper, Guillory, Tavassoli, Lurie, Zweifach, Foss-Feig, Halpern, Trelles and Mss. Rowe, Rouhandeh, George-Jones, Weissman, Mulhern, Brittenham have reported no biomedical financial interests or potential conflicts of interest. Author Contributions Conceptualization: Siper, Tavassoli, Foss-Feig, Gordon, Zemon, Buxbaum, Kolevzon Data curation: Siper, Rowe, Rouhandeh, George-Jones, Lurie, Zweifach, Weissman, Mulhern, Brittenham, Zemon Formal analysis: Siper, Rowe, Guillory, Foss-Feig, Gordon, Zemon Funding acquisition: Siper, Buxbaum, Kolevzon Investigation: Siper, Rowe, Rouhandeh, George-Jones, Tavassoli, Lurie, Zweifach, Weissman, Foss-Feig, Halpern, Trelles, Mulhern, Kolevzon Methodology: Siper, Gordon, Zemon Project administration: Siper, Rowe, George-Jones, Weissman, Buxbaum, Kolevzon Resources: Siper, Gordon, Zemon, Buxbaum, Kolevzon Software: Siper Supervision: Siper, Foss-Feig, Halpern, Gordon, Zemon, Buxbaum, Kolevzon Validation: Siper, Guillory, Rouhandeh, George-Jones, Zweifach, Foss-Feig, Zemon Visualization: Siper, Guillory, Lurie, Brittenham, Gordon, Zemon Writing – original draft: Siper, Guillory Writing – review and editing: Siper, Rowe, Guillory, Rouhandeh, George-Jones, Tavassoli, Lurie, Zweifach, Weissman, Foss-Feig, Halpern, Trelles, Mulhern, Brittenham, Gordon, Zemon, Buxbaum, Kolevzon
Publisher Copyright:
© 2021 American Academy of Child and Adolescent Psychiatry
PY - 2022/4
Y1 - 2022/4
N2 - Objective: The current study used visual evoked potentials (VEPs) to examine excitatory and inhibitory postsynaptic activity in children with Phelan-McDermid syndrome (PMS) and the association with genetic factors. PMS is caused by haploinsufficiency of SHANK3 on chromosome 22 and represents a common single-gene cause of autism spectrum disorder (ASD) and intellectual disability. Method: Transient VEPs were obtained from 175 children, including 31 with PMS, 79 with idiopathic ASD, 45 typically developing controls, and 20 unaffected siblings of children with PMS. Stimuli included standard and short-duration contrast-reversing checkerboard conditions, and the reliability between these 2 conditions was assessed. Test−retest reliability and correlations with deletion size were explored in the group with PMS. Results: Children with PMS and, to a lesser extent, those with idiopathic ASD displayed significantly smaller amplitudes and decreased beta and gamma band activity relative to TD controls and PMS siblings. Across groups, high intraclass correlation coefficients were obtained between standard and short-duration conditions. In children with PMS, test−retest reliability was strong. Deletion size was significantly correlated with P60-N75 amplitude for both conditions. Conclusion: Children with PMS displayed distinct transient VEP waveform abnormalities in both time and frequency domains that might reflect underlying glutamatergic deficits that were associated with deletion size. A similar response pattern was observed in a subset of children with idiopathic ASD. VEPs offer a noninvasive measure of excitatory and inhibitory neurotransmission that holds promise for stratification and surrogate endpoints in ongoing clinical trials in PMS and ASD.
AB - Objective: The current study used visual evoked potentials (VEPs) to examine excitatory and inhibitory postsynaptic activity in children with Phelan-McDermid syndrome (PMS) and the association with genetic factors. PMS is caused by haploinsufficiency of SHANK3 on chromosome 22 and represents a common single-gene cause of autism spectrum disorder (ASD) and intellectual disability. Method: Transient VEPs were obtained from 175 children, including 31 with PMS, 79 with idiopathic ASD, 45 typically developing controls, and 20 unaffected siblings of children with PMS. Stimuli included standard and short-duration contrast-reversing checkerboard conditions, and the reliability between these 2 conditions was assessed. Test−retest reliability and correlations with deletion size were explored in the group with PMS. Results: Children with PMS and, to a lesser extent, those with idiopathic ASD displayed significantly smaller amplitudes and decreased beta and gamma band activity relative to TD controls and PMS siblings. Across groups, high intraclass correlation coefficients were obtained between standard and short-duration conditions. In children with PMS, test−retest reliability was strong. Deletion size was significantly correlated with P60-N75 amplitude for both conditions. Conclusion: Children with PMS displayed distinct transient VEP waveform abnormalities in both time and frequency domains that might reflect underlying glutamatergic deficits that were associated with deletion size. A similar response pattern was observed in a subset of children with idiopathic ASD. VEPs offer a noninvasive measure of excitatory and inhibitory neurotransmission that holds promise for stratification and surrogate endpoints in ongoing clinical trials in PMS and ASD.
KW - Phelan-McDermid syndrome
KW - autism spectrum disorder
KW - transient VEP
KW - visual evoked potential
UR - http://www.scopus.com/inward/record.url?scp=85113457148&partnerID=8YFLogxK
U2 - 10.1016/j.jaac.2021.07.006
DO - 10.1016/j.jaac.2021.07.006
M3 - Article
C2 - 34303785
AN - SCOPUS:85113457148
SN - 0890-8567
VL - 61
SP - 565-574.e1
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 4
ER -